Skip to main content

New Drug Approvals 2012 - Pt. IV - Vismodegib (ERIVEDGETM)

Image
By Bissan Al-Lazikani






Wikipedia: Vismodegib

On Jan 31st 2012 the FDA approved Vismodegib (tradename: ErivedgeTM, previously known as GDC-0449 and HhAntag691) a hedgehog signalling pathway inhibitor for the treatment metastatic basal cell carcinoma.

This is a novel first-in-class medicine, which for the first time modulates the hedgehog pathway. The target of Vismodegib is smoothened (SMO) (UniProt:Q99835, CanSAR:link). SMO is a class F (or class 6) G-Protein Coupled Receptor (GPCR) also known as the Frizzled/Smoothened class (pfam:PF01534). Smoothened is distinct and different to the previously 'drugged' GPCRs (which primarily target class A/class 1 receptors). The 3D-structures of smoothened or any of its homologues have not been characterised and are believed to differ from Class 1 GPCRs.

Vismodegib (Chembl: CHEMBL473417, ChemSpider:23337846 PubChem:CID24776445, IUPAC: 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide) is a synthetic small molecule drug, and is fully rule-of-five compliant. The molecular weight is 421.3, and has an XlogP of 3.8). Normal dosing is 150 mg per day (equivalent to 356 umol).

Vismodegib is a highly permeable compound with low aqueous solubility (BCS Class 2) - the single dose absolute bioavailability of vismodegib is 31.8%. Absorption of vismodegib is saturable - shown by the lack of dose proportional increase in exposure after a single dose of 270 mg or 540 mg vismodegib.  The volume of distribution (Vd) of vismodegib ranges from 16.4 to 26.6 L, and plasma protein binding is greater than 99% - with binding observed to both human serum albumin (ALB) and alpha-1-acid glycoprotein (also known as Orosomucoid, ORM, AGP and AAG), it is also a substrate of the efflux transporter P-glycoprotein (P-gp). Greater than 98% of the total circulating drug-related components are the parent drug. Minor metabolic pathways of vismodegib in humans include oxidation, glucuronidation, and pyridine ring cleavage. Vismodegib and its metabolites are eliminated primarily by the hepatic route with 82% of the administered dose recovered in the feces and less than 5% in urine. The estimated elimination half-life (t1/2) of vismodegib is 4 days after continuous once-daily dosing, and 12 days after a single dose.

Vismodegib has a boxed warning for potential risk of causing embryonic death and serious birth defects.

The license for Vismodegib is held by Genentech.

Full Prescribing Information can be found here.
Labels:

Comments

Post a Comment

Popular posts from this blog

LSH-based similarity search in MongoDB is faster than postgres cartridge.

By
TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p
7 comments
Read more

A python client for accessing ChEMBL web services

By
Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d
1 comment
Read more

Natural Product-likeness in ChEMBL

By
Recently, we included a Natural Product-likeness score for chemical compounds stored in ChEMBL. We made use of an algorithm published by Peter Ertl, Silvio Roggo and Ansgar Schuffenhauer in 2008 .  Whereas the original version of this algorithm used a commercial data set of Natural Product molecules for training the algorithm (the CRC Dictionary of Natural Products) and an in-house library of synthetic molecules as a negative set, we used Greg Landrum's  RDKit implementation  which is based on  ~50,000 natural products collected from various open databases and ~1 million drug-like molecules from ZINC as a "non-Natural Product background". After including the new score into ChEMBL, we were interested to see whether the results look meaningful. We had a handful of simple questions: How is Natural Product-likeness distributed in ChEMBL and how does this compare to Natural Product-likeness for "real" NPs? Can we observe any difference in Natural Product-likeness for
Post a Comment
Read more

What is Max Phase in ChEMBL?

By
ChEMBL contains information on drugs that have been approved for treatment of a specific disease / diagnosis (an indication) within a region of the world (e.g. FDA drugs are approved for use in the United States), and clinical candidate drugs that are being investigated for an indication during the clinical trials process.  The maximum phase of development for the compound across all indications is assigned a category called 'max_phase' (the value in brackets is used in the downloadable ChEMBL database in the 'molecule_dictionary' table): Approved (4): A marketed drug e.g. AMINOPHYLLINE ( CHEMBL1370561 ) is an FDA approved drug for treatment of asthma.  Phase 3 (3): A clinical candidate drug in Phase 3 Clinical Trials e.g. TEGOPRAZAN ( CHEMBL4297583 ) is under clinical investigation for treatment of peptic ulcer at Phase 3, and also liver disease at Phase 1.  Phase 2 (2): A clinical candidate drug in Phase 2 Clinical Trials e.g. NEVANIMIBE HYDROCHLORIDE ( CHEMBL542103 )
Post a Comment
Read more

ChEMBL 32 is released!

By Eloy
  We are pleased to announce the release of ChEMBL 32! This release of ChEMBL comes with a complete update of drug and clinical candidate information, the addition on a Natural Product likeness score and a harmonization of Journal Name abbreviations according to NLM standards. This version of the database, prepared on 26/01/2023 contains: 2,354,965 compounds (of which 2,327,928 have mol files)             2,995,433 compound records (non-unique compounds) 20,038,828 activities 1,536,903 assays 15,139 targets 86,364 documents   Please see ChEMBL 32 release notes for full details of all changes in this release. Data can be downloaded from the ChEMBL FTP site . Please note that on demand Oracle 19c dumps will not be provided anymore after the ChEMBL 34 release. New Deposited Datasets CHEMBL5058649 - Data for DCP probe BAY 1816032 * CHEMBL5058643 - Data for DCP probe BI-2081 * CHEMBL5058646 - Data for DCP probe CCT369260 * CHEMBL5058644 - Data for DCP probe JNJ-39758979 * CHEMBL5058645 - D
Post a Comment
Read more